Jamie L. Reynoso, the CEO of $CLOV, sold 4,913 shares of the company on 12-18-2025 for an estimated $12,822. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.2% of their shares of this class of stock. Following this trade, they now own 2,767,240 shares of this class of $CLOV stock.
$CLOV Insider Trading Activity
$CLOV insiders have traded $CLOV stock on the open market 14 times in the past 6 months. Of those trades, 4 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $CLOV stock by insiders over the last 6 months:
- VIVEK GARIPALLI has made 2 purchases buying 446,980 shares for an estimated $998,996 and 0 sales.
- CONRAD WAI (CEO, Counterpart Health) has made 0 purchases and 2 sales selling 209,797 shares for an estimated $692,968.
- JAMIE L. REYNOSO (CEO, Medicare Advantage) has made 0 purchases and 8 sales selling 87,362 shares for an estimated $263,048.
- ANNA U LOENGARD has made 2 purchases buying 26,500 shares for an estimated $68,755 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CLOV Hedge Fund Activity
We have seen 90 institutional investors add shares of $CLOV stock to their portfolio, and 133 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BANK OF AMERICA CORP /DE/ removed 3,879,613 shares (-96.7%) from their portfolio in Q3 2025, for an estimated $11,871,615
- MARSHALL WACE, LLP removed 3,523,047 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $10,780,523
- RENAISSANCE TECHNOLOGIES LLC removed 2,780,900 shares (-26.5%) from their portfolio in Q3 2025, for an estimated $8,509,554
- DIVISADERO STREET CAPITAL MANAGEMENT, LP added 2,768,088 shares (+inf%) to their portfolio in Q3 2025, for an estimated $8,470,349
- CITADEL ADVISORS LLC removed 2,042,721 shares (-57.9%) from their portfolio in Q3 2025, for an estimated $6,250,726
- QUBE RESEARCH & TECHNOLOGIES LTD removed 1,746,937 shares (-82.6%) from their portfolio in Q3 2025, for an estimated $5,345,627
- GOLDMAN SACHS GROUP INC removed 1,494,774 shares (-63.3%) from their portfolio in Q3 2025, for an estimated $4,574,008
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CLOV Revenue
$CLOV had revenues of $496.6M in Q3 2025. This is an increase of 50.05% from the same period in the prior year.
You can track CLOV financials on Quiver Quantitative's CLOV stock page.
$CLOV Analyst Ratings
Wall Street analysts have issued reports on $CLOV in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 11/06/2025
To track analyst ratings and price targets for $CLOV, check out Quiver Quantitative's $CLOV forecast page.
$CLOV Price Targets
Multiple analysts have issued price targets for $CLOV recently. We have seen 2 analysts offer price targets for $CLOV in the last 6 months, with a median target of $3.35.
Here are some recent targets:
- Richard Close from Canaccord Genuity set a target price of $3.7 on 11/06/2025
- Jonathan Yong from UBS set a target price of $3.0 on 08/06/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
